Volker Germaschewski

This inventor holds 17 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Antibody Therapeutics. Top assignees: Glaxo Group Limited, Glaxosmithkline LLC, Glaxogrouplimited. Active years: 2009-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Volker Germaschewski. Retrieved from https://idiyas.com/inventor/volker-germaschewski

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 3)

% Patents Active = 23.5

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 42(Granted Patents)

Company Filing History:

Years Active: 2009-2020

Loading Chart...

Areas of Expertise:

Anti-IL-18 Antibodies

Antigen Binding Proteins

Humanized Antibodies

Stroke Treatment

Immunoglobulins

Beta-Amyloid Antibodies

Compounds

Functional Fragments

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10703814 - Method of treatment with humanized anti-IL-18 antibodies (2020-07-07),

2. 10221234 - Antigen binding proteins (2019-03-05),

3. 9499617 - Humanized anti-IL-18 antibodies (2016-11-22),

4. 9434716 - Antigen binding proteins (2016-09-06),

5. 9193784 - Antibodies (2015-11-24),

6. 8974782 - Treatment of stroke comprising anti-MAG antibodies (2015-03-10),

7. 8921523 - Humanized anti-beta-amyloid antibodies (2014-12-30),

8. 8858943 - Antigen binding proteins (2014-10-14),

9. 8828384 - Compounds (2014-09-09),

10. 8637018 - Humanized anti-IL-18 antibodies (2014-01-28),

11. 8496932 - Compounds (2013-07-30),

12. 8362208 - Immunoglobulins (2013-01-29),

13. 8227576 - Antibodies against amyloid-β peptide (2012-07-24),

14. 8133978 - Humanised anti-interleukin-18 antibody (2012-03-13),

15. 8071731 - Humanised anti-MAG antibody or functional fragment thereof (2011-12-06),

Title: Volker Germaschewski: Pioneering Innovator in Antibody Therapeutics

Introduction: Volker Germaschewski, a prominent inventor based in Stevenage, GB, holds an impressive portfolio of 17 patents. His work primarily focuses on innovative therapies utilizing humanized anti-IL-18 antibodies and antigen binding proteins, which have significant implications for treating various diseases.

Latest Patents: Among his latest inventions, the method of treatment with humanized anti-IL-18 antibodies stands out. This patent discloses the creation of humanized antibodies, outlines their manufacture, and details methods for their application in treatment. Critical to this invention are screening methods, such as surface plasmon resonance, designed to identify antibodies with therapeutic potential. Additionally, Germaschewski's patent regarding antigen binding proteins covers those that bind to serum amyloid P component (SAP). It includes the encoding polynucleotides, pharmaceutical compositions, and manufacturing methods. Notably, these antigen binding proteins are designed for treating diseases linked to amyloid deposition, including systemic amyloidosis, local amyloidosis, Alzheimer’s disease, and type 2 diabetes.

Career Highlights: Volker Germaschewski has contributed significantly to the field of biomedicine during his career. He has worked with renowned companies such as Glaxo Group Limited and GlaxoSmithKline LLC, where he honed his skills in pharmaceutical innovation and research.

Collaborations: Throughout his career, Germaschewski has collaborated with notable colleagues in the industry, including Jonathan Henry Ellis and Susannah Karen Ford. Their combined expertise has fostered advancements in antibody therapies.

Conclusion: Volker Germaschewski is a distinguished inventor whose contributions to biomedicine have paved the way for innovative treatments. His latest patents not only showcase his dedication to advancing therapeutic options but also highlight his role within esteemed companies and collaborations in the field. The impact of his work continues to be felt as research on antibody therapies progresses.

Profile summary based on public USPTO records.